Effects of Rowachol on prevention of postcholecystectomy pain after laparoscopic cholecystectomy: prospective multicenter randomized controlled trial. Issue 8 (August 2016)

• Record Type: Journal Article
• Authors: Han, In Woong; Kwon, O. Choel; Oh, Min Gu; Choi, Yoo Shin; Lee, Seung Eun
• Is Part Of: HPB. Volume 18:Issue 8(2016)
• Page Start: 664
• Page End: 670
• Publication Date: 2016-08
• Subjects: Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 616.362005
• DOI: 10.1016/j.hpb.2016.05.013
• Languages: English
• ISSNs: 1365-182X

Abstract

Abstract: Background: Postcholecystectomy pain (PCP) is characterized by abdominal pain after cholecystectomy. However, prevention of PCP is not well known yet. The purpose of this study was to determine whether Rowachol might be useful in preventing PCP. Methods: Between May 2013 and January 2014, a total of 138 patients with gallbladder disease who were scheduled to undergo laparoscopic cholecystectomy were randomly assigned to orally receive 100 mg Rowachol or placebo three times daily for 3 months after surgery. Abdominal pain was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire. Results: Incidence of PCP in the placebo group ( n = 9, 14.3%) was higher than that in the Rowachol group ( n = 3, 4.7%) with statistically marginal significance ( P = 0.08). Risk factor analysis implicated PCP with increased difficulty in performing LC, more frequent pathology with acute cholecystitis, and absence of postoperative Rowachol treatment. Multivariate analysis revealed that greater difficulty of laparoscopic cholecystectomy (HR = 5.78, 95% CI 1.36–24.40, P < 0.05), and absence of postoperative Rowachol treatment (HR = 2.54, 95% CI 1.10–10.39, P < 0.05) were independent risk factors for development of PCP. Conclusion: Rowachol might be beneficial for prevention of PCP after laparoscopic cholecystectomy.